How to organise travel restrictions in the new future: lessons from the COVID-19 response in Hong Kong and Singapore.
COVID-19
control strategies
health policy
public health
review
Journal
BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
21
07
2021
accepted:
01
02
2022
entrez:
1
3
2022
pubmed:
2
3
2022
medline:
8
3
2022
Statut:
ppublish
Résumé
It has been nearly 2 years since the first case of COVID-19 was reported. Governments worldwide have introduced numerous non-pharmaceutical interventions (NPIs) to combat this disease. Many of these NPIs were designed in response to initial outbreaks but are unsustainable in the long term. Governments are exploring how to adjust their current NPIs to resume normal activities while effectively protecting their population. As one of the most controversial NPIs, the implementation of travel restrictions varies across regions. Some governments have abandoned their previous travel restrictions because of the induced costs to society and on the economy. Other areas, including Hong Kong (Special Administrative Region of China) and Singapore, continue employing these NPIs as a long-term disease prevention tactic. However, the multidimensional impacts of travel restrictions require careful consideration of how to apply restrictions more appropriately. We have proposed an adapted framework to examine Hong Kong and Singapore's travel restrictions. We aimed to study these two regions' experiences in balancing disease control efforts with easing the burden on lives and livelihoods. Based on the experiences of Hong Kong and Singapore, we have outlined six policy recommendations to serve as the cornerstone for future research and policy practices.
Identifiants
pubmed: 35228258
pii: bmjgh-2021-006975
doi: 10.1136/bmjgh-2021-006975
pmc: PMC8886091
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
BMJ Glob Health. 2021 Mar;6(3):
pubmed: 33722793
Clin Rev Allergy Immunol. 2021 Sep 18;:
pubmed: 34536214
Lancet Microbe. 2021 Feb;2(2):e79-e87
pubmed: 33495759
Lancet. 2021 Jun 12;397(10291):2234-2236
pubmed: 33932328
Lancet. 2020 Nov 7;396(10261):1525-1534
pubmed: 32979936
Lancet. 2021 Mar 13;397(10278):1023-1034
pubmed: 33587887
J Migr Health. 2021;3:100037
pubmed: 33817682
J Glob Health. 2021 Jul 03;11:03086
pubmed: 34221356
Science. 2020 Apr 24;368(6489):395-400
pubmed: 32144116
Clin Infect Dis. 2021 Jul 1;73(1):137-142
pubmed: 32756996
JAMA. 2021 Apr 13;325(14):1389-1390
pubmed: 33662092
Lancet Reg Health West Pac. 2021 Jul 20;13:100209
pubmed: 34527991
Cell. 2021 Mar 4;184(5):1127-1132
pubmed: 33581746
Nat Commun. 2021 Jan 11;12(1):232
pubmed: 33431829
JAMA Netw Open. 2021 May 3;4(5):e2110918
pubmed: 34009347
Lancet Public Health. 2021 Mar;6(3):e175-e183
pubmed: 33484644
Lancet. 2021 Oct 30;398(10311):1547-1551
pubmed: 34619099
J Am Med Dir Assoc. 2021 Dec;22(12):2515-2516
pubmed: 34678265
Lancet Public Health. 2021 Jan;6(1):e12-e20
pubmed: 33301722
Lancet Reg Health West Pac. 2021 May;10:100130
pubmed: 33778795
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Global Health. 2021 Jun 21;17(1):62
pubmed: 34154597
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
JAMA. 2021 Mar 2;325(9):821-822
pubmed: 33507218
Lancet. 2020 Mar 14;395(10227):912-920
pubmed: 32112714
Lancet Infect Dis. 2021 Jul;21(7):929-938
pubmed: 33765417
J Med Ethics. 2021 May 14;:
pubmed: 33990428
Lancet. 2020 May 23;395(10237):1593-1595
pubmed: 32416788